Imagine waiting years for a treatment that could slow your disease, only to find out your doctor didn't prescribe it. This happens more often than you think.
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic condition that causes fluid-filled sacs to grow in your kidneys. Over 12 million people worldwide have this disease. In the UK alone, 30,000 to 70,000 people live with it.
Right now, there is only one drug approved to slow the disease's progress. It is called tolvaptan. Doctors have clear rules on who should get this medicine. But a new look at UK data shows these rules are not always followed.
The surprising shift
Researchers checked records from 72 different kidney centers across the UK. They looked at who got the drug and who did not. The results were not what anyone expected.
About one-third of patients who met the rules for treatment did not get it. At the same time, about one-quarter of patients who got the drug did not meet the rules. This means some people are missing out on help while others might be getting it when they shouldn't.
What scientists didn't expect
Think of the drug like a special key for a specific lock. The lock represents the disease progression in a patient's kidneys. The key is tolvaptan. It only works if the lock is the right shape.
In the study, many patients had the wrong lock shape. They were not eligible for the key. Yet, doctors still gave them the key. Other patients had the perfect lock, but no one gave them the key. This mix-up costs money and hurts patient care.
The team used data from the National Registry of Rare Kidney Diseases. They looked at records from 2016 to 2023. They studied 3,609 people with ADPKD. The data came from routine hospital records, not special tests.
The biggest issue is that eligible patients are being left behind. Nearly 35% of patients who should have taken the drug did not start it. This gap varies from one center to another. Some centers prescribe the drug much more often than others.
This inconsistency could cost the NHS up to 53.7 million pounds in savings. It also means patients lose out on better quality of life. The drug could have helped them live longer with better kidney function.
This doesn't mean this treatment is available yet.
There is another problem. Some patients are taking the drug when they are not eligible. This costs the system about 15.9 million pounds. It also puts strain on resources that could be used elsewhere.
These findings show that doctors make different decisions in different places. This is not good for fairness. Patients with rare diseases deserve equal access to the best treatments.
Next steps involve talking to doctors and health officials. They need to follow the national guidelines more closely. Training might help doctors understand who truly needs the drug.
Would you consider this if it becomes available?
If this treatment becomes widely available, would you discuss it with your doctor? Is this something you'd want to know about before making a decision?
Early symptoms of kidney disease How to talk to your doctor about rare diseases Ways to lower chronic disease risk